We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

559 hedge funds and large institutions have $11.4B invested in Abiomed Inc in 2019 Q1 according to their latest regulatory filings, with 88 funds opening new positions, 213 increasing their positions, 188 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

66% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 53

13% more repeat investments, than reductions

Existing positions increased: 213 | Existing positions reduced: 188

6% more funds holding

Funds holding: 529559 (+30)

11% less capital invested

Capital invested by funds: $12.8B → $11.4B (-$1.45B)

45% less call options, than puts

Call options by funds: $165M | Put options by funds: $300M

54% less funds holding in top 10

Funds holding in top 10: 136 (-7)

Holders
559
Holders Change
+30
Holders Change %
+5.67%
% of All Funds
12.1%
Holding in Top 10
6
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-53.85%
% of All Funds
0.13%
New
88
Increased
213
Reduced
188
Closed
53
Calls
$165M
Puts
$300M
Net Calls
-$135M
Net Calls Change
-$50.5M
Name Holding Trade Value Shares
Change
Change in
Stake
New York State Common Retirement Fund
26
New York State Common Retirement Fund
New York
$69.6M -$2.58M -7,749 -3%
William Blair & Company
27
William Blair & Company
Illinois
$69.3M +$1.74M +5,244 +2%
Invesco
28
Invesco
Georgia
$68.4M +$10.9M +32,702 +16%
T. Rowe Price Associates
29
T. Rowe Price Associates
Maryland
$67.5M +$6.66M +20,034 +9%
Ameriprise
30
Ameriprise
Minnesota
$62.9M +$40M +120,451 +121%
GGHC
31
Gilder Gagnon Howe & Co
New York
$62.4M -$876K -2,637 -1%
CTA
32
Carillon Tower Advisers
Florida
$62M +$13.8M +41,589 +24%
Victory Capital Management
33
Victory Capital Management
Texas
$59.1M +$16.2M +48,771 +31%
MWNA
34
Marshall Wace North America
New York
$54.4M +$3.72M +11,194 +6%
CS
35
Credit Suisse
Switzerland
$54.3M +$4.63M +13,919 +8%
William Blair Investment Management
36
William Blair Investment Management
Illinois
$53.1M +$19.4M +58,242 +46%
FCM
37
Frontier Capital Management
Massachusetts
$52.9M +$1.91M +5,755 +3%
EAM
38
Eagle Asset Management
Florida
$50.9M +$12.2M +36,703 +26%
Citadel Advisors
39
Citadel Advisors
Florida
$50.7M +$58.3M +175,370 +8,195%
Charles Schwab
40
Charles Schwab
California
$50.5M +$2.46M +7,395 +4%
CIBC Private Wealth Group
41
CIBC Private Wealth Group
Georgia
$50.4M +$1.61M +4,855 +3%
Deutsche Bank
42
Deutsche Bank
Germany
$50.3M -$27.3M -82,035 -32%
Sumitomo Mitsui Trust Group
43
Sumitomo Mitsui Trust Group
Japan
$48.7M -$4.26M -12,813 -7%
Aberdeen Group
44
Aberdeen Group
United Kingdom
$45.8M +$3.75M +11,278 +8%
SIMG
45
Stephens Investment Management Group
Texas
$45.3M +$430K +1,294 +0.8%
Macquarie Group
46
Macquarie Group
Australia
$44.2M +$37.3M +112,122 +263%
Two Sigma Advisers
47
Two Sigma Advisers
New York
$43.4M -$6.41M -19,300 -11%
Neuberger Berman Group
48
Neuberger Berman Group
New York
$42.9M -$193K -582 -0.4%
Morgan Stanley
49
Morgan Stanley
New York
$42.2M -$2.47M -7,429 -5%
Mitsubishi UFJ Trust & Banking
50
Mitsubishi UFJ Trust & Banking
Japan
$41.9M +$298K +897 +0.6%

ABMD Hedge Fund Activity: Q1 2019 in Review

559 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q1 2019, worth a combined $11.4B — down 11% from $12.8B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new ABMD positions and 53 closed out — a net gain of 35 holders — while 213 added to existing stakes and 188 trimmed.

The largest buyer was Amundi Asset Management US, adding an estimated $163M. The largest seller was Winslow Capital Management, exiting entirely with an estimated $170M sold.

  • 559 institutional investors held Abiomed Inc (ABMD) as of Q1 2019, up from 529 in Q4 2018.
  • Funds reported $11.4B of Abiomed Inc stock for Q1 2019, down 11% quarter-over-quarter.
  • 88 funds opened new Abiomed Inc positions in Q1 2019 and 53 closed out, a net change of +35 holders.
  • The largest Abiomed Inc buyer in Q1 2019 was Amundi Asset Management US, an estimated $163M added.
  • The largest Abiomed Inc seller in Q1 2019 was Winslow Capital Management, an estimated $170M sold.

Based on aggregated 13F filings for Q1 2019.